Floatz logo

nkt3447

CCNE1 Amplification

NiKang Therapeutics, Inc.Phase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

12 Active assets in the CCNE1 Amplification cohort.

Asset / SponsorPhaseRating
LEUPROLIDE
Avenzo Therapeutics, Inc.
Phase 1/2CCC
Letrozole
Avenzo Therapeutics, Inc.
Phase 1/2CCC
FULVESTRANT
Avenzo Therapeutics, Inc.
Phase 1/2CCC
Zoladex
Avenzo Therapeutics, Inc.
Phase 1/2CCC
Carboplatin
Avenzo Therapeutics, Inc.
Phase 1/2CCC

View all 12 →

Same molecule, other indications

nkt3447 is also rated in:

endometrial disorderDormant
CC
Indicative ·
43 / 100
View asset →
metastatic neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
gastric carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →